We are live on ! Find out more
CYTO

Altamira Therapeutics Ltd
CYTO

Delisted

CYTO was delisted on the 19th of December, 2024.

Back to rankings

9 hedge funds and large institutions have $11.7M invested in Altamira Therapeutics Ltd in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more funds holding

Funds holding: 4 → 9 (+5)

20% more capital invested

Capital invested by funds: $9.75M → $11.7M (+$1.96M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
9
Holders Change
+5
Holders Change %
+125%
% of All Funds
0.22%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SMV
Sofinnova Management VIII
California
+$2.01M
2
UOC
UBS O'Connor
Illinois
+$962K
3
PA
Perceptive Advisors
New York
+$401K
4
Morgan Stanley
Morgan Stanley
New York
+$160K
5
SM
Sabby Management
Florida
+$160K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$36K
2
CS
Credit Suisse
Switzerland
-$31K
3
Goldman Sachs
Goldman Sachs
New York
-$25K
4
Millennium Management
Millennium Management
New York
-$25K
5
VKH
Virtu KCG Holdings
New York
-$22K
Name Holding Trade Value Shares
Change 		Change in
Stake
SMV
1
Sofinnova Management VIII
California
$7.19M +$2.01M +25 +34%
BG
2
Bellevue Group
Switzerland
$2M – – –
UOC
3
UBS O'Connor
Illinois
$909K +$962K +12 New
TCM
4
Tekla Capital Management
Massachusetts
$712K – – –
PA
5
Perceptive Advisors
New York
$368K +$401K +5 New
Morgan Stanley
6
Morgan Stanley
New York
$138K +$160K +2 New
SM
7
Sabby Management
Florida
$133K +$160K +2 New
WA
8
Wasatch Advisors
Utah
$107K – – –
WS
9
Wedbush Securities
California
$41K +$80.2K +1 New
SPC
10
Sigma Planning Corp
Michigan
$24K – – –
KeyBank National Association
11
KeyBank National Association
Ohio
$22K – – –
Citadel Advisors
12
Citadel Advisors
Florida
$20K – – –
Geode Capital Management
13
Geode Capital Management
Massachusetts
$15K – – –
AS
14
Arxis Securities
New York
$11K – – –
ARTA
15
A.R.T. Advisors
New York
$10K – – –
CG
16
Cutler Group
California
$10K – – –
UBS Group
17
UBS Group
Switzerland
$2K – – –
Creative Planning
18
Creative Planning
Kansas
$1K – – –
AIM
19
Acrospire Investment Management
Illinois
– -$13K – –
CS
20
Credit Suisse
Switzerland
– -$31K – –
Goldman Sachs
21
Goldman Sachs
New York
– -$25K – –
Group One Trading
22
Group One Trading
Illinois
– -$4K – –
Millennium Management
23
Millennium Management
New York
– -$25K – –
Susquehanna International Group
24
Susquehanna International Group
Pennsylvania
– -$36K – –
VKH
25
Virtu KCG Holdings
New York
– -$22K – –

CYTO Hedge Fund Activity: Q1 2017 in Review

9 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Altamira Therapeutics Ltd (CYTO) for Q1 2017, worth a combined $11.7M — up 20% from $9.75M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new CYTO positions and 0 closed out — a net gain of 5 holders — while 1 added to existing stakes and 0 trimmed.

The largest buyer was Sofinnova Management VIII, adding an estimated $2.01M. The largest seller was Susquehanna International Group, cutting an estimated $36K.

  • 9 institutional investors held Altamira Therapeutics Ltd (CYTO) as of Q1 2017, up from 4 in Q4 2016.
  • Funds reported $11.7M of Altamira Therapeutics Ltd stock for Q1 2017, up 20% quarter-over-quarter.
  • 5 funds opened new Altamira Therapeutics Ltd positions in Q1 2017 and 0 closed out, a net change of +5 holders.
  • The largest Altamira Therapeutics Ltd buyer in Q1 2017 was Sofinnova Management VIII, an estimated $2.01M added.
  • The largest Altamira Therapeutics Ltd seller in Q1 2017 was Susquehanna International Group, an estimated $36K sold.

Based on aggregated 13F filings for Q1 2017.